Amycretin is a first-in-class unimolecular peptide co-agonist developed by Novo Nordisk that simultaneously activates both GLP-1 and amylin receptors from a single molecule. It is being developed primarily as an oral tablet for obesity treatment. In the Phase 2 REDEFINE 1 trial, oral amycretin produced up to 13.1% body weight loss at 36 weeks — remarkable for an oral peptide formulation. Unlike orforglipron (a small-molecule oral GLP-1 agonist), amycretin is a true peptide with dual receptor engagement. Phase 3 trials expected to begin in 2026.
Category: Weight Loss / GLP-1 Agonist. Evidence rating: C (early/mixed human evidence).
Clinical status: Phase 2 completed (REDEFINE 1). Phase 3 expected 2026. Investigational — not approved anywhere.
Amycretin simultaneously activates two receptor systems from a single molecular backbone. The GLP-1 receptor component promotes glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central nervous system signaling (similar to semaglutide/liraglutide). The…
Safety considerations: Most common adverse events are gastrointestinal: nausea, vomiting, diarrhea (consistent with GLP-1 agonist class); GI effects generally mild to moderate, occurring during dose escalation and diminishing with continued treatment; Phase 1 trial (Gasiorek et al., Lancet 2025) reported generally well tolerated across dose ranges.
Reviewed by the PeptideAtlas Editorial Team.
| Half-life | ~46 hours |
|---|---|
| Bioavailability | Oral (proprietary peptide delivery technology) |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Investigational. Not FDA-approved. Phase 3 trials expected 2026. |
While semaglutide acts solely on GLP-1 receptors, amycretin engages both GLP-1 and amylin receptors from one molecule. Preclinical data shows superior weight loss vs semaglutide alone. Amycretin is also being developed primarily as an oral tablet.
CagriSema combines two separate injectable peptides (cagrilintide + semaglutide) achieving ~22.7% weight loss at 68 weeks. Amycretin achieves dual activity from a single oral molecule — different value proposition (convenience vs maximum efficacy).
Amycretin is a genuine peptide engineered for oral bioavailability and dual receptor activity. This distinguishes it from small-molecule oral GLP-1 agonists like orforglipron, which cannot engage amylin receptors.
Phase 3 trials are expected to begin in 2026. If successful, regulatory submissions would follow — placing potential market availability several years away.
Coverage on this site: Oral Wegovy Outruns Foundayo in the First Full Quarter of Oral Competition.